An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer

Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer

(2021) Gillian Vandekerkhove et al.   Nature Communications

Rucaparib for recurrent, locally advanced, or metastatic urothelial carcinoma (mUC): Results from ATLAS, a phase II open-label trial.

(2020) Petros Grivas et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis

(2020) Ann Taber et al.   Nature Communications

Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade

(2020) Qu Zhang et al.   Cancer Discovery

Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma

(2019) Emil Christensen et al.   JOURNAL OF CLINICAL ONCOLOGY

Role of Targeted Therapies in Management of Metastatic Urothelial Cancer in the Era of Immunotherapy

(2019) Petros Grivas et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

(2019) Yohann Loriot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer

(2019) Alessandro Leonetti et al.   BRITISH JOURNAL OF CANCER

A Consensus Molecular Classification of Muscle-invasive Bladder Cancer

(2019) Aurélie Kamoun et al.   EUROPEAN UROLOGY

Co‐mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer

(2019) Puyuan Xing et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial

(2019) Michael Friedlander et al.   LANCET ONCOLOGY

Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

(2019) Thomas Powles et al.   NATURE MEDICINE

Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer

(2019) Seyed Pairawan et al.   CLINICAL CANCER RESEARCH

Exceptional response to olaparib in BRCA2 -altered urothelial carcinoma after PD-L1 inhibitor and chemotherapy failure

(2018) Andrea Necchi et al.   EUROPEAN JOURNAL OF CANCER

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

(2018) Thomas Powles et al.   LANCET

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

(2018) Sanjeev Mariathasan et al.   NATURE

Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer

(2017) Robert J. Jones et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

(2017) Joaquim Bellmunt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

(2017) Thomas Powles et al.   JAMA Oncology

Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

(2016) Christophe Massard et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy

(2014) Woonyoung Choi et al.   CANCER CELL

Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib

(2014) N. Wagle et al.   Cancer Discovery

Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens

(2010) Joaquim Bellmunt et al.   JOURNAL OF CLINICAL ONCOLOGY

Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies: Figure 1.

(2008) Jorge A. Garcia et al.   MOLECULAR CANCER THERAPEUTICS